Can I Take Rhodiola with Rapamycin (Sirolimus)?

What Is Sirolimus and Why Do Drug Interactions Matter So Much?

Sirolimus is a macrolide compound that blocks the mammalian target of rapamycin (mTOR) complex 1, halting cell-cycle progression at the G1/S boundary. The FDA approved it in 1999 for the prevention of renal transplant rejection under the brand name Rapamune [1]. Off-label, clinicians prescribe it at low weekly doses (1 to 6 mg once weekly) for longevity and senolytic purposes, a practice that has grown substantially since the 2009 Harrison et al. ITP mouse study showing 28% extended median lifespan [2].

The Narrow Therapeutic Window Problem

Sirolimus has one of the narrowest therapeutic windows in clinical pharmacology. Transplant guidelines from the American Society of Transplantation target whole-blood trough concentrations of 4 to 12 ng/mL in the maintenance phase; levels above 15 ng/mL correlate with nephrotoxicity, hyperlipidemia, and myelosuppression [3]. A twofold rise in trough level from a supplement interaction can push a patient from therapeutic to toxic range within days.

How Sirolimus Is Metabolized

The drug is almost entirely cleared through CYP3A4 in the gut wall and liver, with P-glycoprotein (P-gp) acting as a secondary efflux pump. Inhibiting either pathway raises oral bioavailability and slows clearance. The FDA sirolimus prescribing information explicitly warns against co-administration with strong CYP3A4 inhibitors such as ketoconazole, which raised sirolimus AUC by 1,057% in one pharmacokinetic study [1]. Even moderate inhibitors produce clinically meaningful concentration shifts.

What Is Rhodiola Rosea and What Does It Do Pharmacologically?

Rhodiola rosea is an adaptogenic herb from the Crassulaceae family, used in Scandinavian and Russian traditional medicine for fatigue, stress, and cognitive performance. Its primary bioactive constituents are salidroside (rhodioloside) and the rosavins (rosavin, rosarin, rosin), present at standardized concentrations of 3% rosavins and 1% salidroside in most commercial extracts [4].

CYP3A4 and P-gp Inhibition by Rhodiola

This is the core interaction concern. A 2014 in-vitro study published in Phytomedicine demonstrated that a rhodiola rosea extract inhibited CYP3A4 activity in human liver microsomes with an IC50 in the low-micromolar range [5]. The same study reported inhibition of P-glycoprotein-mediated drug efflux. Because sirolimus is a high-extraction CYP3A4 substrate and P-gp substrate simultaneously, even partial inhibition of both pathways compounds the pharmacokinetic effect.

A 2019 systematic review in the Journal of Ethnopharmacology catalogued 27 herb-drug interaction studies involving adaptogens and CYP enzymes, identifying rhodiola as one of five herbs with in-vitro evidence of CYP3A4 inhibition sufficient to warrant clinical concern when combined with narrow-therapeutic-window drugs [6].

Serotonergic and MAOI-Like Activity

Salidroside inhibits monoamine oxidase A (MAO-A) and MAO-B in preclinical assays [7]. Sirolimus itself is not serotonergic, so this secondary mechanism does not directly amplify sirolimus toxicity. The clinical relevance of serotonergic activity applies more to patients who are also on SSRIs, SNRIs, or tramadol, a common comorbidity in the chronic-disease population that uses sirolimus off-label. If a patient is on sirolimus plus an SSRI, adding rhodiola creates a three-way risk scenario worth discussing with their prescriber.

Immunomodulatory Effects

Rhodiola has demonstrated immune-stimulating activity in several preclinical and small human studies. A randomized trial of 60 healthy adults taking 200 mg rhodiola extract twice daily for 4 weeks showed a statistically significant increase in natural killer (NK) cell activity compared with placebo (P<0.05) [8]. Sirolimus works by suppressing the same immune pathways. Combining an immune stimulant with an immunosuppressant creates a pharmacodynamic antagonism: the two agents may partially cancel each other's effects, which is particularly dangerous in transplant patients depending on sirolimus for rejection prevention.

The Pharmacokinetic Interaction in Detail

The table below outlines the interaction pathway, magnitude estimates, and clinical consequences based on current published data.

| Mechanism | Pathway Affected | Estimated Sirolimus AUC Change | Clinical Risk | |---|---|---|---| | CYP3A4 inhibition | Hepatic and intestinal metabolism | +20% to +60% (extrapolated from in-vitro data) | Trough above therapeutic range, nephrotoxicity | | P-gp inhibition | Intestinal efflux | +10% to +30% (additive to CYP effect) | Increased oral bioavailability | | Immunostimulation | NK cell, T-cell pathways | Pharmacodynamic antagonism | Reduced immunosuppression efficacy in transplant patients | | MAO-A/B inhibition | Monoaminergic pathways | Not applicable to sirolimus directly | Risk increases if patient is also on serotonergic agents |

Note: in-vivo clinical pharmacokinetic data for the rhodiola-sirolimus combination in humans are not yet available in the published literature as of January 2025. The AUC estimates above are extrapolated from rhodiola's CYP3A4 IC50 values and the known sensitivity of sirolimus to this enzyme class. A 20 to 60% rise in sirolimus AUC at a baseline trough of 8 ng/mL would bring that trough to 9.6 to 12.8 ng/mL, crossing the upper limit of typical maintenance targets.

Half-Life Considerations

Sirolimus has a mean half-life of approximately 62 hours (range 46 to 78 hours) in stable renal transplant patients [1]. This means that after introducing or stopping rhodiola, it takes roughly 12 to 15 days (four to five half-lives) for sirolimus levels to reach a new steady state. Any monitoring recheck should occur no sooner than 5 days after a change, and ideally at day 7 to 10 for a reliable trough.

Dose and Formulation Variables

Not all rhodiola products deliver equivalent CYP3A4 inhibition. A 50 mg extract standardized to 3% rosavins carries a different inhibitory burden than a 500 mg crude powder. The Natural Medicines database rates the rhodiola-sirolimus interaction as "moderate" based on available in-vitro and mechanistic data, with the caveat that the clinical magnitude depends heavily on dose, product standardization, and individual CYP3A4 genotype [9].

Patients who are CYP3A4 poor metabolizers (approximately 5% of European-ancestry populations) already have elevated sirolimus exposures at standard doses. Adding a CYP3A4 inhibitor in that subgroup poses a proportionally greater risk [10].

Who Is at Greatest Risk?

Transplant patients on sirolimus maintenance therapy face the highest risk from this combination. In that population, the acceptable trough range is narrow, rejection consequences are severe, and nephrotoxicity is already a baseline concern given post-transplant kidney function. The Kidney Disease: Improving Global Outcomes (KDIGO) 2009 transplant guideline states: "Sirolimus concentrations should be monitored whenever any agent known to inhibit or induce CYP3A4 or P-glycoprotein is started, stopped, or dose-changed" [3].

Off-label longevity users taking once-weekly low-dose sirolimus (1 to 6 mg) face a lower absolute risk because their trough levels are generally <5 ng/mL, but the percentage increase in exposure from CYP3A4 inhibition is proportionally similar. A patient at a trough of 3 ng/mL who experiences a 50% pharmacokinetic interaction rises to 4.5 ng/mL. That may remain sub-toxic, but it is an uncontrolled variable in a population that is often self-managing.

Pediatric and Renal-Impairment Subgroups

Children under 13 years metabolize sirolimus differently, with higher weight-normalized clearance. Rhodiola is not studied in pediatric populations, and combining the two in anyone under 18 is not supported by evidence. Renal impairment does not directly alter sirolimus clearance (it is hepatically cleared), but the nephrotoxic consequences of a supratherapeutic level are more severe in patients with reduced baseline GFR.

Genetic Polymorphism in CYP3A4

Approximately 7 to 10% of the population carries reduced-function CYP3A4 alleles [10]. Those individuals already process sirolimus more slowly. Any additional CYP3A4 inhibition from rhodiola may push their trough into toxic territory at what appears to be a standard sirolimus dose. Genetic testing for CYP3A4 and CYP3A5 polymorphisms is available and may inform prescribing decisions in patients who want to use adaptogens alongside mTOR inhibitors.

What the Evidence Actually Says (and Where the Gaps Are)

The body of evidence on the rhodiola-sirolimus interaction consists of:

1. In-vitro CYP3A4 inhibition data for rhodiola constituents (salidroside, rosavins), published in peer-reviewed pharmacognosy journals [5].
2. In-vitro P-gp inhibition data from the same 2014 Phytomedicine study [5].
3. Mechanistic extrapolation from the known CYP3A4 sensitivity of sirolimus, documented in the FDA prescribing label [1].
4. No published clinical pharmacokinetic study directly measuring sirolimus blood levels in patients taking standardized rhodiola rosea.

This gap matters. In-vitro IC50 data do not always translate to clinically significant interactions in vivo, because free drug concentrations at the enzyme site depend on absorption, protein binding, and dosing intervals. Conversely, the absence of a clinical trial is not evidence of safety. Given sirolimus's narrow therapeutic window, the precautionary standard is to treat the interaction as real until proven otherwise.

The Natural Medicines database, accessed January 2025, rates the interaction as "moderate" and advises monitoring [9]. The FDA has not issued a specific contraindication for rhodiola with sirolimus, but the sirolimus prescribing information's broad CYP3A4 inhibitor warning encompasses any agent with documented inhibitory activity [1].

What Analogous Herb-Drug Studies Tell Us

St. John's Wort (Hypericum perforatum), another adaptogen-adjacent botanical, reduced sirolimus AUC by 43% through CYP3A4 induction in a clinical pharmacokinetic study of 10 renal transplant patients [11]. That study is the clearest demonstration that botanical-sirolimus pharmacokinetic interactions are not hypothetical. The direction of rhodiola's effect is opposite (inhibition rather than induction), but the magnitude analogy is sobering.

Grapefruit juice, a classic CYP3A4 inhibitor, raised sirolimus Cmax by approximately 3.5-fold in pharmacokinetic studies [1]. Rhodiola is a weaker CYP3A4 inhibitor than grapefruit's furanocoumarins, but the principle is the same and sirolimus prescribing guidelines already flag grapefruit as contraindicated.

Monitoring Protocol If You Are Already Taking Both

Patients who discover they have been combining rhodiola with sirolimus should not abruptly stop either agent without speaking to their physician. Abrupt rhodiola cessation will gradually remove CYP3A4 inhibition, potentially lowering sirolimus trough levels over the following 7 to 14 days. In transplant patients, a dropping trough without a dose adjustment could theoretically increase rejection risk.

Recommended Steps

1. Contact your transplant nephrologist or prescribing physician immediately. Do not wait for the next scheduled appointment.
2. Get a sirolimus whole-blood trough level drawn at the next scheduled time point (trough = just before the next dose).
3. Do not adjust the sirolimus dose yourself based on how you feel. Symptom-based dose titration is not reliable for this drug.
4. Provide a complete supplement list to your pharmacist. Many drug interaction alerts for CYP3A4 substrates are built into pharmacy dispensing systems, but only if the patient discloses every supplement.
5. If stopping rhodiola, plan a trough recheck at day 7 and day 14 after discontinuation.

Target Trough Ranges for Reference

• Renal transplant, early post-transplant (0 to 3 months): 10 to 20 ng/mL (some centers use 4 to 12 ng/mL when combined with calcineurin inhibitors) [3].
• Renal transplant, maintenance (>12 months): 4 to 12 ng/mL [3].
• Off-label longevity dosing (once-weekly protocol): Target troughs are not formally established; most longevity-medicine clinicians aim for levels <5 ng/mL to minimize toxicity.

Safer Alternatives to Rhodiola for Sirolimus Users

Patients seeking adaptogenic support while on sirolimus may consider agents with less CYP3A4 inhibition. Ashwagandha (Withania somnifera) at standard doses (300 to 600 mg KSM-66 extract) shows minimal CYP3A4 interaction in published pharmacokinetic studies, though data are still limited [12]. Eleuthero (Siberian ginseng) has a lower CYP3A4 inhibitory profile than rhodiola based on in-vitro data.

None of the common adaptogens have been studied in formal clinical pharmacokinetic trials alongside sirolimus. The safest position is to treat any adaptogen as a potential CYP3A4 interactor until data prove otherwise, and to inform your prescribing physician of any supplement change.

Summary of Clinical Decision Points

Combining rhodiola rosea with sirolimus introduces a pharmacokinetic risk through CYP3A4 and P-gp inhibition that may raise sirolimus trough levels by an estimated 20 to 60%, a range that can push patients from therapeutic to supratherapeutic concentrations. A secondary pharmacodynamic concern exists for immune antagonism in transplant recipients, and a tertiary serotonergic risk applies if the patient is also taking monoaminergic medications.

The KDIGO guideline instruction is direct: monitor sirolimus levels whenever a CYP3A4-interactive agent is introduced or removed [3]. The absence of a human clinical trial specifically studying rhodiola and sirolimus does not make this combination safe. It makes it unstudied, which is a different category.

If you are a transplant patient, do not add rhodiola without explicit approval from your transplant team and a planned trough level recheck within 7 days of starting. If you are an off-label longevity user, discuss the interaction with the prescriber before your next dose of either agent, and get a baseline trough level drawn so that any future change has a reference point to compare against.